Internal Medicine, Hematology & Oncology · Thousand Oaks, CA
NPI
1861495475
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
425 Haaland Dr Ste 101
Thousand Oaks, CA, 91361
Phone (805) 496-2949
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
187,345 services
Medicare patients, 2024
465
Average age 76
Drug cost, 2024
$1.5M
436 prescriptions
Company payments, 2025
$63.37
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ashwin Kashyap was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 33,850 times for 24 patients. In total Ashwin Kashyap billed 187,345 services in 127 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 33,850 | 24 | $2.34 | $79K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,750 | 18 | $0.87 | $22K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,200 | 14 | $44.73 | $501K |
| J0185 Injection, aprepitant, 1 mg | Office | 9,620 | 22 | $1.33 | $13K |
| J0897 Injection, denosumab, 1 mg | Office | 8,220 | 25 | $20.60 | $169K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,024 | 40 | $0.07 | $148 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,010 | 29 | $0.09 | $90.23 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 787 | 11 | $3.35 | $2,637 |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 744 | 21 | $116.23 | $86K |
| 99214 Office E&M - Established | Office | 702 | 307 | $103.95 | $73K |
| 99215 Office E&M - Established | Office | 642 | 227 | $153.10 | $98K |
| 96372 Injection Administration | Office | 440 | 81 | $12.82 | $5,643 |
| J9190 Injection, fluorouracil, 500 mg | Office | 424 | 11 | $2.27 | $963 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 385 | 224 | $13.94 | $5,368 |
| 96413 Chemotherapy Administration | Office | 359 | 67 | $121.23 | $44K |
By year: 2022 $2.7M for 146,658 services; 2023 $2.3M for 135,612 services; 2024 $3.2M for 187,345 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ashwin Kashyap prescribed most often to Medicare patients was Eliquis (Apixaban), with 40 prescriptions and refills. In total Ashwin Kashyap wrote 436 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 40 | 53 | 11 | $30K |
| Tamoxifen Citrate Generic | 35 | 93 | 12 | $877 |
| Ondansetron Hcl Generic | 32 | 32 | 16 | $110 |
| Anastrozole Generic | 26 | 72 | Under 11 | $674 |
| Hydroxyurea Generic | 24 | 49 | Under 11 | $197 |
| Xtandi Enzalutamide | 20 | 20 | Under 11 | $271K |
| Allopurinol Generic | 19 | 33 | Under 11 | $41.38 |
| Revlimid Lenalidomide | 19 | 19 | Under 11 | $363K |
| Dexamethasone Generic | 19 | 28 | 11 | $349 |
| Acyclovir Generic | 15 | 23 | Under 11 | $235 |
| Prednisone Generic | 14 | 22 | Under 11 | $30.26 |
| Prochlorperazine Maleate Generic | 14 | 14 | 11 | $165 |
| Gefitinib Generic | 12 | 12 | Under 11 | $51K |
| Tagrisso Osimertinib Mesylate | 11 | 11 | Under 11 | $176K |
Brand drugs: - claims; generic drugs: 286 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ashwin Kashyap $63.37 ($63.37 in general payments such as food, travel and fees) from 2 companies. The largest payer was Amgen Inc. with $32.72.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.